Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Understanding failure in targeted breast cancer therapy

Dr Martin Jechlinger - EMBL Monterotondo, Rome, Italy
Understanding failure in targeted breast cancer therapy ( Dr Martin Jechlinger - EMBL Monterotondo, Rome, Italy )
21 Jul 2015

De-activating chromosomes to prevent cancer

Dr Philip Avner - Head of EMBL Monterotondo, Milan, Italy
De-activating chromosomes to prevent cancer ( Dr Philip Avner - Head of EMBL Monterotondo, Milan, Italy )
21 Jul 2015

From stem cell to cancer stem cell

Prof Paolo Di Fiore - IFOM-IEO, Milan, Italy
From stem cell to cancer stem cell ( Prof Paolo Di Fiore - IFOM-IEO, Milan, Italy )
21 Jul 2015

From innovation to improved patient care: challenges for foundations and cancer research organisations

Dr Jacques Raynaud - Association pour la recherche sur le cancer (ARC), Villejuif, France
From innovation to improved patient care: challenges for foundations and cancer research organisations ( Dr Jacques Raynaud - Association pour la recherche sur le cancer (ARC), Villejuif, France )
6 Jul 2015

The importance of target expression in personalised medicine

Dr Paolo Nuciforo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
The importance of target expression in personalised medicine ( Dr Paolo Nuciforo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
6 Jul 2015

Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast

Prof Bin Tean Teh - National Singapore Cancer Center, Singapore
Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast ( Prof Bin Tean Teh - National Singapore Cancer Center, Singapore )
3 Jul 2015

Chemoresistance and residual disease promoted by DNMT3A R882 in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA
Chemoresistance and residual disease promoted by DNMT3A R882 in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Jun 2015

Exploring "bad luck" - why do some patients develop myeloid leukaemia?

Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK
Exploring "bad luck" - why do some patients develop myeloid leukaemia? ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )
13 Jun 2015

Genomic sequencing to find AML-causing mutations

Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK
Genomic sequencing to find AML-causing mutations ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )
13 Jun 2015

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA
DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )
12 Jun 2015

ecancermedicalscience editor's choice for May 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for May 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
26 May 2015

WIN 2015: Oncologists and industry working together for personalised medicine

Prof Razelle Kurzrock - University of California, San Diego, USA
WIN 2015: Oncologists and industry working together for personalised medicine ( Prof Razelle Kurzrock - University of California, San Diego, USA )
13 May 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation